# Wyndham H. Wilson

Source: https://onco.cc/people/wyndham-wilson/  
OnCo record `wyndham-wilson` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Developed dose-adjusted EPOCH-R, the regimen that cures primary mediastinal B-cell lymphoma without radiotherapy.

## Summary

Wyndham Wilson developed the infusional dose-adjusted EPOCH regimen and showed that DA-EPOCH-R cures primary mediastinal B-cell lymphoma in more than 90% of patients without radiotherapy, and led the NCI studies of ibrutinib in ABC-subtype DLBCL that linked molecular subtype to treatment response. He co-led the Alliance/CALGB 50303 trial comparing DA-EPOCH-R with R-CHOP and studies of Burkitt lymphoma with reduced-intensity therapy.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: lymphoma; nci; chemotherapy
- Role: Senior Investigator and Head, Lymphoma Therapeutics Section, National Cancer Institute Center for Cancer Research
- Specialisms: Aggressive lymphoma; Dose-adjusted EPOCH; Primary mediastinal lymphoma; Molecular subtypes

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Wilson%20WH%5BAuthor%5D%20lymphoma%20EPOCH

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Primary mediastinal (thymic) large B-cell lymphoma](https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/)
- targets: [CD20](https://onco.cc/targets/cd20/)
- institutions: [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/), [NCI Center for Cancer Research (intramural programme)](https://onco.cc/institutions/nci-ccr/)

---
JSON: https://onco.cc/api/v1/entities/wyndham-wilson.json